Cargando…

The Impact of China’s Zero Markup Drug Policy on Hospitalization Expenses for Inpatients in Tertiary Public Hospitals: Evidence Based on Quantile Difference-in-Difference Models

Objectives: The aim of this study was to determine the impact of the Zero Markup drug (ZMD) policy on hospitalization expenses for inpatients in tertiary Chinese hospitals. Methods: Using the administrative data from hospital electronic health records (EHRs) between 2015 and 2017, we implemented the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Ziling, Jia, Jie, Cui, Lu, Zhou, Siyu, Wang, Xiaohe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307609/
https://www.ncbi.nlm.nih.gov/pubmed/34356286
http://dx.doi.org/10.3390/healthcare9070908
_version_ 1783728088610242560
author Ni, Ziling
Jia, Jie
Cui, Lu
Zhou, Siyu
Wang, Xiaohe
author_facet Ni, Ziling
Jia, Jie
Cui, Lu
Zhou, Siyu
Wang, Xiaohe
author_sort Ni, Ziling
collection PubMed
description Objectives: The aim of this study was to determine the impact of the Zero Markup drug (ZMD) policy on hospitalization expenses for inpatients in tertiary Chinese hospitals. Methods: Using the administrative data from hospital electronic health records (EHRs) between 2015 and 2017, we implemented the quantile difference-in-differences (QDID) estimators to evaluate the impact of the ZMD policy on hospitalization expenses while controlling for patient-level and hospital-level characteristics. Results: According to the QDID models, the introduction of ZMD policy significantly induced lower drug costs for all inpatients especially at the 50th (-USD 507.84 (SE = USD 90.91), 75th (-USD 844.77 (SE = USD 149.70), and 90th (-USD 1400.00 (SE = USD 209.97)) percentiles of the overall distributions. However, the total hospitalization, diagnostic, treatment, material and services expenses for inpatients were significantly higher for the treated group than the control group. This tendency was more pronounced for inpatients in tertiary hospitals with lower expenses (in the 10th, 25th and 50th percentiles). Conclusion: The implementation of ZMD policy alone may not be enough to change the medical service providers’ profit-driven behavior. The targeted supervision of hospital costs by the Chinese health administration department should be strengthened to avoid unreasonable hospital charges.
format Online
Article
Text
id pubmed-8307609
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83076092021-07-25 The Impact of China’s Zero Markup Drug Policy on Hospitalization Expenses for Inpatients in Tertiary Public Hospitals: Evidence Based on Quantile Difference-in-Difference Models Ni, Ziling Jia, Jie Cui, Lu Zhou, Siyu Wang, Xiaohe Healthcare (Basel) Article Objectives: The aim of this study was to determine the impact of the Zero Markup drug (ZMD) policy on hospitalization expenses for inpatients in tertiary Chinese hospitals. Methods: Using the administrative data from hospital electronic health records (EHRs) between 2015 and 2017, we implemented the quantile difference-in-differences (QDID) estimators to evaluate the impact of the ZMD policy on hospitalization expenses while controlling for patient-level and hospital-level characteristics. Results: According to the QDID models, the introduction of ZMD policy significantly induced lower drug costs for all inpatients especially at the 50th (-USD 507.84 (SE = USD 90.91), 75th (-USD 844.77 (SE = USD 149.70), and 90th (-USD 1400.00 (SE = USD 209.97)) percentiles of the overall distributions. However, the total hospitalization, diagnostic, treatment, material and services expenses for inpatients were significantly higher for the treated group than the control group. This tendency was more pronounced for inpatients in tertiary hospitals with lower expenses (in the 10th, 25th and 50th percentiles). Conclusion: The implementation of ZMD policy alone may not be enough to change the medical service providers’ profit-driven behavior. The targeted supervision of hospital costs by the Chinese health administration department should be strengthened to avoid unreasonable hospital charges. MDPI 2021-07-18 /pmc/articles/PMC8307609/ /pubmed/34356286 http://dx.doi.org/10.3390/healthcare9070908 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ni, Ziling
Jia, Jie
Cui, Lu
Zhou, Siyu
Wang, Xiaohe
The Impact of China’s Zero Markup Drug Policy on Hospitalization Expenses for Inpatients in Tertiary Public Hospitals: Evidence Based on Quantile Difference-in-Difference Models
title The Impact of China’s Zero Markup Drug Policy on Hospitalization Expenses for Inpatients in Tertiary Public Hospitals: Evidence Based on Quantile Difference-in-Difference Models
title_full The Impact of China’s Zero Markup Drug Policy on Hospitalization Expenses for Inpatients in Tertiary Public Hospitals: Evidence Based on Quantile Difference-in-Difference Models
title_fullStr The Impact of China’s Zero Markup Drug Policy on Hospitalization Expenses for Inpatients in Tertiary Public Hospitals: Evidence Based on Quantile Difference-in-Difference Models
title_full_unstemmed The Impact of China’s Zero Markup Drug Policy on Hospitalization Expenses for Inpatients in Tertiary Public Hospitals: Evidence Based on Quantile Difference-in-Difference Models
title_short The Impact of China’s Zero Markup Drug Policy on Hospitalization Expenses for Inpatients in Tertiary Public Hospitals: Evidence Based on Quantile Difference-in-Difference Models
title_sort impact of china’s zero markup drug policy on hospitalization expenses for inpatients in tertiary public hospitals: evidence based on quantile difference-in-difference models
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307609/
https://www.ncbi.nlm.nih.gov/pubmed/34356286
http://dx.doi.org/10.3390/healthcare9070908
work_keys_str_mv AT niziling theimpactofchinaszeromarkupdrugpolicyonhospitalizationexpensesforinpatientsintertiarypublichospitalsevidencebasedonquantiledifferenceindifferencemodels
AT jiajie theimpactofchinaszeromarkupdrugpolicyonhospitalizationexpensesforinpatientsintertiarypublichospitalsevidencebasedonquantiledifferenceindifferencemodels
AT cuilu theimpactofchinaszeromarkupdrugpolicyonhospitalizationexpensesforinpatientsintertiarypublichospitalsevidencebasedonquantiledifferenceindifferencemodels
AT zhousiyu theimpactofchinaszeromarkupdrugpolicyonhospitalizationexpensesforinpatientsintertiarypublichospitalsevidencebasedonquantiledifferenceindifferencemodels
AT wangxiaohe theimpactofchinaszeromarkupdrugpolicyonhospitalizationexpensesforinpatientsintertiarypublichospitalsevidencebasedonquantiledifferenceindifferencemodels
AT niziling impactofchinaszeromarkupdrugpolicyonhospitalizationexpensesforinpatientsintertiarypublichospitalsevidencebasedonquantiledifferenceindifferencemodels
AT jiajie impactofchinaszeromarkupdrugpolicyonhospitalizationexpensesforinpatientsintertiarypublichospitalsevidencebasedonquantiledifferenceindifferencemodels
AT cuilu impactofchinaszeromarkupdrugpolicyonhospitalizationexpensesforinpatientsintertiarypublichospitalsevidencebasedonquantiledifferenceindifferencemodels
AT zhousiyu impactofchinaszeromarkupdrugpolicyonhospitalizationexpensesforinpatientsintertiarypublichospitalsevidencebasedonquantiledifferenceindifferencemodels
AT wangxiaohe impactofchinaszeromarkupdrugpolicyonhospitalizationexpensesforinpatientsintertiarypublichospitalsevidencebasedonquantiledifferenceindifferencemodels